TEVA

17.26

2.86% 0.48

Handel nachbörslich: 17.34 0.08 +0.46%

Teva Pharmaceutical Industries Ltd Adr (TEVA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt TEVA? Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$16.78

Offen:

$16.87

24-Stunden-Volumen:

9.48M

Relative Volume:

0.80

Marktkapitalisierung:

$19.79B

Einnahmen:

$16.54B

Nettoeinkommen (Verlust:

$-1.64B

KGV:

-11.90

EPS:

-1.45

Netto-Cashflow:

$749.00M

1W Leistung:

+1.77%

1M Leistung:

+6.61%

6M Leistung:

+3.66%

1J Leistung:

+1.95%

1-Tages-Spanne:

$16.52

$17.28

1-Wochen-Bereich:

$16.52

$18.28

52-Wochen-Spanne:

$12.46

$22.80

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile

Firmenname

Teva Pharmaceutical Industries Ltd Adr

Sektor

Healthcare (1166)

Branche

Drug Manufacturers - Specialty & Generic (1)

Telefon

972 (3) 914-8213

Adresse

TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV

Mitarbeiter

35,686

Twitter

@TevaUSA

Nächster Verdiensttermin

2025-01-29

Neueste SEC-Einreichungen

TEVA's Discussions on Twitter

Vergleichen Sie TEVA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TEVA Teva Pharmaceutical Industries Ltd Adr	17.26	20.31B	16.54B	-1.64B	749.00M	-1.45
HLN Haleon Plc Adr	11.41	50.54B	14.35B	1.85B	0	0.4023
ZTS Zoetis Inc	169.42	74.02B	9.29B	2.52B	2.28B	5.57
RDHL Redhill Biopharma Ltd Adr	1.80	4.22M	35.75M	11.57M	-26.25M	-3.8069
TAK Takeda Pharmaceutical Co Adr	15.08	45.82B	30.08B	710.16M	4.45B	0.2182

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-05-28	Eingeleitet	Truist	Buy
2025-05-12	Hochstufung	JP Morgan	Neutral → Overweight
2024-07-10	Hochstufung	Argus	Hold → Buy
2024-03-08	Hochstufung	JP Morgan	Underweight → Neutral
2024-02-12	Hochstufung	Piper Sandler	Neutral → Overweight
2024-01-23	Hochstufung	Jefferies	Hold → Buy
2024-01-03	Hochstufung	Piper Sandler	Underweight → Neutral
2023-12-18	Eingeleitet	HSBC Securities	Buy
2023-11-27	Hochstufung	UBS	Neutral → Buy
2023-07-06	Hochstufung	UBS	Sell → Neutral
2023-05-25	Eingeleitet	Morgan Stanley	Equal-Weight
2023-05-18	Hochstufung	Evercore ISI	In-line → Outperform
2023-01-19	Herabstufung	Jefferies	Buy → Hold
2022-11-14	Herabstufung	JP Morgan	Neutral → Underweight
2022-11-04	Herabstufung	UBS	Neutral → Sell
2022-10-21	Fortgesetzt	Jefferies	Buy
2022-08-05	Hochstufung	BofA Securities	Neutral → Buy
2022-06-14	Fortgesetzt	UBS	Neutral
2022-05-17	Hochstufung	BofA Securities	Underperform → Neutral
2022-05-04	Herabstufung	Piper Sandler	Neutral → Underweight
2022-04-05	Hochstufung	Barclays	Equal Weight → Overweight
2022-03-25	Hochstufung	Bernstein	Mkt Perform → Outperform
2022-01-27	Herabstufung	Argus	Buy → Hold
2021-10-28	Herabstufung	Raymond James	Outperform → Mkt Perform
2021-05-04	Herabstufung	UBS	Buy → Neutral
2021-04-07	Fortgesetzt	RBC Capital Mkts	Sector Perform
2020-11-25	Eingeleitet	Oppenheimer	Perform
2020-08-06	Hochstufung	Barclays	Underweight → Equal Weight
2020-07-27	Fortgesetzt	Goldman	Neutral
2020-06-01	Hochstufung	SunTrust	Hold → Buy
2020-04-24	Fortgesetzt	Citigroup	Neutral
2020-04-06	Hochstufung	UBS	Neutral → Buy
2020-02-24	Herabstufung	Edward Jones	Hold → Sell
2019-11-12	Hochstufung	JP Morgan	Underweight → Neutral
2019-10-17	Hochstufung	Gabelli & Co	Hold → Buy
2019-08-07	Herabstufung	Evercore ISI	Outperform → In-line
2019-07-19	Eingeleitet	Wolfe Research	Peer Perform
2019-07-15	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2019-07-10	Fortgesetzt	Credit Suisse	Neutral
2019-07-05	Hochstufung	Argus	Hold → Buy
2019-06-11	Eingeleitet	Barclays	Underweight
2019-06-03	Hochstufung	Oppenheimer	Perform → Outperform
2019-05-30	Herabstufung	BofA/Merrill	Buy → Underperform
2019-05-28	Herabstufung	UBS	Buy → Neutral
2019-03-20	Eingeleitet	SunTrust	Hold
2019-03-07	Fortgesetzt	UBS	Buy

Alle ansehen

Teva Pharmaceutical Industries Ltd Adr Aktie (TEVA) Neueste Nachrichten

May 30, 2025

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025 - GlobeNewswire Inc.

May 30, 2025

May 29, 2025

Teva: New Long-Term Targets and Sold Pipeline Reaffirm Our Favorable Outlook; Shares Undervalued - Morningstar

May 29, 2025

May 28, 2025

TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate - Yahoo Finance

May 28, 2025

May 20, 2025

Restart of Student Loan Repayments Could Squeeze Consumer Spending and Slow Economic Growth - iHeart

May 20, 2025

May 19, 2025

Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.

May 19, 2025

May 12, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

May 12, 2025

May 07, 2025

Teva Earnings: Innovation Propels Sales and Generics Show Stability in Solid Start to the Year - Morningstar

May 07, 2025

May 05, 2025

Teva and Alvotech stocks jump on FDA approval of SELARSDI - Investing.com

May 05, 2025

Teva and Alvotech stocks jump on FDA approval of SELARSDI By Investing.com - Investing.com Canada

May 05, 2025

Apr 30, 2025

There Are Mixed Signals on the Chart for Teva- Pharmaceutical Industries Ltd. ADR (TEVA) - uspostnews.com

Apr 30, 2025

Digi Power X Inc (DGXX)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com

Apr 30, 2025

Apr 29, 2025

Market Analysts see Norwegian Cruise Line Holdings Ltd [NCLH] gaining to $21. Time to buy? - dbtnews.com

Apr 29, 2025

PG&E Corp [PCG] Revenue clocked in at $24.54 billion, down -14.37% YTD: What’s Next? - dbtnews.com

Apr 29, 2025

Greenwave Technology Solutions Inc [GWAV] Is Currently 12.13 above its 200 Period Moving Avg: What Does This Mean? – The DBT News - dbtnews.com

Apr 29, 2025